Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers

NCT ID NCT07726368

Not yet recruiting Disease control Sponsor: Eccogene Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial investigates whether ECC4703, a potential new treatment for non-alcoholic fatty liver disease (NAFLD), changes how the body processes two other drugs: sulfasalazine and pitavastatin. Healthy adults aged 18 to 65 will take these drugs alone and then with ECC4703 to measure any differences in drug levels. The goal is to understand possible drug interactions early, ensuring safety for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ECC4703, sulfasalazine, and pitavastatin
What this could lead to
If successful, this trial could help determine safe dosing of ECC4703 with common medications, supporting its development as a treatment for non-alcoholic fatty liver disease.
What could go wrong
This is an early-phase drug interaction study in healthy volunteers, not patients. Results may not predict real-world effects in people with NAFLD, and ECC4703 could still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.